Addex Therapeutics teams up with Dystonia Medical Research Foundation on dipraglurant

19 January 2015

Swiss pharma company Addex Therapeutics (SIX: ADXN) is to enter into a collaboration with the Dystonia Medical Research Foundation to explore the use of dipraglurant to treat dystonia.

Dystonia is the third most common movement disorder (after essential tremor and Parkinson’s disease), and dipraglurant has been shown to normalize the effects of the TOR1A/DYT1 dystonia mutation in the brains of mice.

The objective of the collaboration is to design a detailed development plan and regulatory path as well as identifying key option leaders and patients for a Phase II clinical trial. Addex is also to start clinical testing of the therapeutic effect of dipraglurant in patients with cervical dystonia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK